Short-term decongestion and clinical benefit in acute heart failure: a systematic review and trial-level meta-regression
- 1Department of Cardiology, the Quzhou Affiliated Hospital of Wenzhou Medical University, Quzhou People’s Hospital
Abstract
Background: Body weight, urine output, urinary sodium, and ultrasound findings are frequently used as early trial endpoints in acute heart failure (AHF). However, patient-level prognostic associations with residual congestion do not establish the fact that treatment-induced marker improvement predicts fewer deaths or heart failure events.
Objectives: The objectives of this work are to pair short-term decongestion and subsequent clinical treatment effects within the same randomized comparisons, explore the trial-level association for body weight, and qualitatively assess non-weight markers.
Methods: PubMed/MEDLINE, OpenAlex, and ClinicalTrials.gov databases were searched through 18 July 2026. Eligible randomized adult AHF trials reported an objective decongestion effect and ≥30-day mortality, heart failure events, or rehospitalization. The amended primary marker was weight change at 24–96 h (original window, 48–96 h); clinical effects were log hazard or risk ratios. An errors-in-variables meta-regression model used 10,000 trial cluster bootstrap fits and trial-level jackknife intervals.
Results: Twenty-four trials (27 reports) were accepted for qualitative synthesis; the primary analysis included 12 comparisons from only 10 independent trials. Endpoints, follow-up (30–302 days), effect measures, and mechanisms were heterogeneous. Each additional 1-kg between-group difference in weight loss corresponded to a clinical effect ratio of 0.74 (percentile 95% interval, 0.56–1.26; jackknife, 0.49–1.11). The pharmacological-only estimate was 1.04. Evidence for urine output, urinary sodium, and ultrasound was also inconsistent.
Conclusions: Short-term weight loss showed a directional but non-robust trial-level association with clinical benefit. The randomized trial-level evidence evaluated here is insufficient to validate short-term weight change as a surrogate for post-discharge clinical outcomes in AHF.
Related
- Renal Dysfunction and Cardiorenal Syndrome in Acute Heart Failure: A Systematic Review of Residual Congestion and Decongestion Response
- Pulmonary thromboembolism with prolonged pulmonary infarction during intensive decongestion for severe heart failure : A case report
- Subcutaneous Furosemide for Ambulatory Decongestion in Heart Failure: Outcomes From a High-Risk Real-World Cohort.
- Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials
- Adjunctive pirenoxine is associated with transient tear biomarker changes without sustained ocular surface benefit after refractive surgery: a randomized clinical trial
BibTeX
@article{wang2026shortterm,
title = {{Short-term decongestion and clinical benefit in acute heart failure: a systematic review and trial-level meta-regression}},
author = {Huiming Wang and Hang Fang and Mengqi Wu and Qiang Chen and Anyi Fu and Mengdan Xu},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1942130},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1942130/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Short-term decongestion and clinical benefit in acute heart failure: a systematic review and trial-level meta-regression
AU - Huiming Wang
AU - Hang Fang
AU - Mengqi Wu
AU - Qiang Chen
AU - Anyi Fu
AU - Mengdan Xu
PY - 2026
DA - 2026/10/30
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1942130
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1942130/full
AB - Background: Body weight, urine output, urinary sodium, and ultrasound findings are frequently used as early trial endpoints in acute heart failure (AHF). However, patient-level prognostic associations with residual congestion do not establish the fact that treatment-induced marker improvement predicts fewer deaths or heart failure events. Objectives: The objectives of this work are to pair short-term decongestion and subsequent clinical treatment effects within the same randomized comparisons, explore the trial-level association for body weight, and qualitatively assess non-weight markers. Methods: PubMed/MEDLINE, OpenAlex, and ClinicalTrials.gov databases were searched through 18 July 2026. Eligible randomized adult AHF trials reported an objective decongestion effect and ≥30-day mortality, heart failure events, or rehospitalization. The amended primary marker was weight change at 24–96 h (original window, 48–96 h); clinical effects were log hazard or risk ratios. An errors-in-variables meta-regression model used 10,000 trial cluster bootstrap fits and trial-level jackknife intervals. Results: Twenty-four trials (27 reports) were accepted for qualitative synthesis; the primary analysis included 12 comparisons from only 10 independent trials. Endpoints, follow-up (30–302 days), effect measures, and mechanisms were heterogeneous. Each additional 1-kg between-group difference in weight loss corresponded to a clinical effect ratio of 0.74 (percentile 95% interval, 0.56–1.26; jackknife, 0.49–1.11). The pharmacological-only estimate was 1.04. Evidence for urine output, urinary sodium, and ultrasound was also inconsistent. Conclusions: Short-term weight loss showed a directional but non-robust trial-level association with clinical benefit. The randomized trial-level evidence evaluated here is insufficient to validate short-term weight change as a surrogate for post-discharge clinical outcomes in AHF.
SN - 2297-055X
ER -